Kevin Charles Gorman sold $22M of NBIX
director at NEUROCRINE BIOSCIENCES INC. 146,105 shares at an average of $149.46, traded Jan 27, 2025, filed Jan 29, 2025.
Score components
- +15RoleDirector
- +25Trade size$21.8M at market
- +5Share of holdings soldSold 22% of holdings
- +15Cluster7 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -21.2%, 3m -28.5%, 6m -9.2%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000914475-25-000009, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 27, 2025 | MOption exercise Common Stock10b5-1 | +146,105 | $32.99 | $4.8M | 660,701 | Jan 29, 2025 |
| Jan 27, 2025 | SOpen-market sale Common Stock10b5-1 | -146,105 | $149.46 | $22M | 514,596 | Jan 29, 2025 |
| Jan 27, 2025 | MOption exercise Non-Qualified Stock Optionderivative10b5-1 | -146,105 | $0.00 | $0 | 0 | Jan 29, 2025 |
Related signals
Other insiders at NEUROCRINE BIOSCIENCES INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 32Weak | NEUROCRINE BIOSCIENCES INC | Matt Abernethy Chief Financial Officer | $363k 2,311 shares | -5% | |
| 21Weak | NEUROCRINE BIOSCIENCES INC | David W. Boyer Chief Corp. Affairs Officer | $130k 826 shares | -9% | |
| 10Weak | NEUROCRINE BIOSCIENCES INC | Eric Benevich Chief Commercial Officer | $333k 2,154 shares | -3% | |
| 40Moderate | NEUROCRINE BIOSCIENCES INC | Julie Cooke Chief Human Resources Officer | $5.8M 36,937 shares | -62% | |
| 15Weak | NEUROCRINE BIOSCIENCES INC | Ingrid Delaet Chief Regulatory Officer | $354k 2,261 shares | -12% | |
| 40Moderate | NEUROCRINE BIOSCIENCES INC | David W. Boyer Chief Corp. Affairs Officer | $609k 3,888 shares | -33% | |
| 30Weak | NEUROCRINE BIOSCIENCES INC | Kevin Charles Gorman director | $38M 245,088 shares | -32% | |
| 20Weak | NEUROCRINE BIOSCIENCES INC | Kyle Gano Chief Executive Officer | $4.8M 36,400 shares | -21% | |
| 29Weak | NEUROCRINE BIOSCIENCES INC | Leslie Norwalk V director | $946k 6,190 shares | -50% | |
| 16Weak | NEUROCRINE BIOSCIENCES INC | Darin Lippoldt Chief Legal Officer | $699k 4,376 shares | -9% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.